Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

43 results
Display

Intravenous Zoledronate for a Patient with Paget's Disease

Kim KC

Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Antiresorptive Therapies for Postmenopausal Osteoporosis

Choi HJ

Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects

Martin TJ

  • KMID: 2391949
  • J Bone Metab.
  • 2014 Feb;21(1):8-20.
Bone is continuously remodelled at many sites asynchronously throughout the skeleton, with bone formation and resorption balanced at these sites to retain bone structure. Negative balance resulting in bone loss...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Proper time to initiate antiosteoporotic treatment in rheumatoid arthritis with or without glucocorticoid use

Lee SW

  • KMID: 2070106
  • Korean J Intern Med.
  • 2014 Jul;29(4):434-436.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emerging Anabolic Therapies for Osteoporosis

Choi HJ

Osteoporosis is defined as low bone mineral density (BMD) associated with fragility fractures. It is characterized by unbalanced bone remodeling activity leading to bone loss and eventually fractures. Osteoporosis-related fractures...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures

Min BW, Song KS, Bae KC, Cho CH, Son ES, Lee KJ

Osteoporosis is a metabolic disease that is increasing in prevalence as people live longer. Because the orthopedic surgeon is frequently the first and often the only physician to manage patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent Advances in the Drug Therapy of Osteoporosis

Lee HW

  • KMID: 2320272
  • Yeungnam Univ J Med.
  • 1999 Dec;16(2):155-168.
Osteoporosis is one of the most important public health problems facing the aging population. Drug therapy for osteoporosis can be divided operationally into two main categories: drugs that inhibit bone...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacologic treatment of osteoporosis

Min YK

The objectives of this article are to review current pharmacologic approaches for the treatment of osteoporosis in Korea. Calcium and vitamin D supplementation are necessary for osteoporotic patients with inadequate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical application of quantitative computed tomography in osteogenesis imperfecta-suspected cat

Won S, Chung WJ, Yoon J

One-year-old male Persian cat presented with multiple fractures and no known traumatic history. Marked decrease of bone radiopacity and thin cortices of all long bones were identified on radiography. Tentative...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dental care for patients taking antiresorptive drugs: a literature review

Song M

Antiresorptive drugs (ARDs), such as bisphosphonates or denosumab, that prevent bone resorption are widely used in patients with osteoporosis or with cancer that has metastasized to the bones. Although osteonecrosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Spontaneous Acetabular Periprosthetic Fracture in a Patient Continuously Having Zoledronic Acid

Tantavisut S, Tanavalee , Thanakit V, Ngarmukos , Wilairatana V, Wangroongsub Y

Zoledronic acid has been used for prevention of osteolytic and osteoblastic bone metastasis. This case report illustrates an undesirable consequence from prolonged usage of zoledronic acid in bone metastasis prevention....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change

Nakatoh S

OBJECTIVES: This study aimed to investigate the correlation between bone mineral density (BMD) and the turnover rate [√(MoMf²+ MoMr²), multiple of median formation (MoMf) was calculated as bone-specific alkaline phosphatase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Undertreatment of Osteoporosis Following Hip Fractures in Jeju Cohort Study

Kim SR, Park YG, Kang SY, Nam KW, Park YG, Ha YC

BACKGROUND: Osteoporosis treatment following hip fracture is well known to not enough. We previously performed intervention study for orthopaedic surgeon's education and reported twofold increase in osteoporosis detection and treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analgesic Effects of Antiosteoporotic Drugs

Ahn DK, Shin WS, Kim GW

STUDY DESIGN: Literature review. OBJECTIVES: To propose possible mechanisms of osteoporotic back pain and its management with antiosteoporotic drugs. SUMMARY OF LITERATURE REVIEW: No general conclusion has yet been reached regarding whether...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes of markers of bone turnover and spinal BMD after 1 year treatment according to treatment strategies & predictability of changes of BMD by changes of bone markers in Korean postmenopausal women with osteoporosis

Oh HJ, Oh JK, Lee DB

  • KMID: 2295046
  • J Korean Acad Fam Med.
  • 2001 Aug;22(8):1234-1246.
BACKGROUND: Increased BMD after treatment means that the treatment regimen was effective to prevent fracture associated with osteoporosis. But changes of BMD reflected at least after 1 year. Now we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cyclic Pamidronate Infusion in Primary Osteoporotic Women

Chae BN, Hong EG, Lee SK, Chung YS, Lee KW, Kim HM

  • KMID: 2199801
  • J Korean Soc Endocrinol.
  • 2001 Apr;16(2):221-230.
BACKGROUND: Bisphosphonates are now well established as successful antiresorptive agents for the prevention and treatment of osteoporosis. We investigated the effect of cyclic intravenous treatment with an aminobisphosphonate, pamidronate in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Living Donor Liver Transplantation for an Infant with Osteogenesis Imperfecta and Intrahepatic Cholestasis: Report of a Case

Choi Y, Yi NJ, Ko JS, Ko JM, Jin US, Kim HS, Lee KH, Cho TJ, Suh SW, Yoo T, Lee KW, Suh KS

Osteogenesis imperfecta (OI) is a group of genetic disorders characterized by bone fragility and connective tissue manifestations. We report a successful liver transplantation (LT) in an 8-month-old boy with OI...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Adequacy of Diagnosis and Treatment for Osteoporosis in Patients with Proximal Humeral Fractures

Kim TI, Choi JH, Kim SH, Oh JH

BACKGROUND: The purpose of this study was to evaluate whether physicians' practice was adequate for the diagnosis and treatment of osteoporosis in patients with proximal humeral fracture over the age...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
3\Month follow up results after alendronate therapy in postmenopausal osteoporosis

Oh HJ, Moon WN, Yoon HK, Han IK

  • KMID: 2295191
  • J Korean Acad Fam Med.
  • 2000 Aug;21(8):1035-1041.
BACKGROUND: Increased bone turnover results in bone loss after menopause. After menopause, the major cause of bone loss is estrogen deficiency. Rate of bone loss seems to increase after menopause...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reference Intervals for Bone Turnover Markers in Korean Healthy Women

Cho DH, Chung JO, Chung MY, Cho JR, Chung DJ

BACKGROUND: Adequate suppression of bone turnover rate is important to decrease fracture risk without mineralization defect due to oversuppression. This study was performed to determine reference intervals (RIs) for 2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr